Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

The trial also showed that Dupixent significantly reduced disease ... The blisters and rash can form over much of the body and cause the skin to bleed and crust, resulting in patients being ...

If approved, Dupixent would be the first and only targeted ... The blisters and rash can form over much of the body and cause the skin to bleed and crust, resulting in patients being more prone ...

Dupixent was previously granted Orphan Drug ... filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2024. Any forward-looking ...